About this trial
This study is based on the hypothesis that the pharmacokinetics of anti-tuberculosis drugs in TB children are different from adults. The investigators aim to study the population pharmacokinetics of children receiving the anti-tuberculsis drugs for treatment of TB. In this study, the investigators will detect drug concentration in plasma by using residual blood samples of blood gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models. In addition, the investigators also want to correlate use of anti-tuberculsis drugs with treatment effectiveness and incidence of adverse effects in children. This novel knowledge will allow better and more rational approaches to the treatment of TB in children. It will also set the foundation for further studies to improve anti-tuberculosis drug therapies for children.
Eligibility criteria
Qualifiers
Children (0-18 years old) with anti-tuberculosis therapy against TB.
The anti-tuberculsis therapy includes drugs commonly used in children infectious diseases
Informed consent signed by the parents and/or guardians.
Disqualifiers
Anti-tuberculosis drugs aren't involved in the therapies of children.
It is unable to provide complete medical records or the current condition cannot accept the study process.
Patients are allergic to anti-tuberculsis drugs.
Parents and/or guardians do not agree to participate in this study.
Trial design
Treatments tested in this trial
- anti-tuberculosis drug
Treatment groups
Sponsors and collaborators
Beijing Children's Hospital
Lead sponsor
Shandong University
Collaborator
Hopital Universitaire Robert-Debre
Collaborator
Rennes University Hospital
Collaborator